Cerus Corp (CERS) 4.50 $CERS
Financial Results Schedules, Approvals, Appointments, Product Launches, and Stock Movements - Analyst Notes on Allergan, Accuray, Cerus, Galena Biopharma, and ZELTIQ Aesthetic
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY), Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ: GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cerus Submits the Medical Device License Application to Health Canada for INTERCEPT Plasma
Business Wire - Mon Apr 07, 7:31AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that it has submitted its Medical Device license application to Health Canada for review of the INTERCEPT Blood system for plasma. This follows an agreement reached with Health Canada in November of last year to pursue regulatory submissions for both INTERCEPT platelets and plasma. Cerus plans to file its regulatory submission for platelets in the second quarter of 2014.
Shares of CERS Down 17.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 03, 11:19AM CDT
SmarTrend identified a Downtrend for Cerus (NASDAQ:CERS) on March 12th, 2014 at $6.04. In approximately 3 weeks, Cerus has returned 17.05% as of today's recent price of $5.01.
Cerus Down 16.6% Since SmarTrend Downtrend Call (CERS)
Comtex SmarTrend(R) - Thu Mar 27, 9:51AM CDT
SmarTrend identified a Downtrend for Cerus (NASDAQ:CERS) on March 12th, 2014 at $6.04. In approximately 2 weeks, Cerus has returned 16.56% as of today's recent price of $5.04.
Partnership to Initiate Development of Whole Blood Pathogen Inactivation for Sub-Saharan Africa
Business Wire - Wed Mar 26, 7:31AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that the Humanitarian Foundation Swiss Red Cross has granted funds to Swiss Tranfusion SRC (Blutspende SRK Schweiz) to adapt the INTERCEPT Blood System for red blood cells for pathogen inactivation and transfusion of whole blood, specifically for sub-Saharan African countries. The initial funding of 1.5 million Swiss Francs will support the feasibility phase of the project and completion of in vitro studies to support patient clinical trials.
Frank Witney Joins Cerus Board of Directors
Business Wire - Tue Mar 25, 7:31AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that Dr. Frank Witney, president and chief executive officer of Affymetrix, has joined its board of directors and the compensation committee. Dr. Witney joins the board with over 30 years of experience in the life science industry, specifically focused on corporate strategy and commercialization of products in the life science tools and diagnostics space. Dr. Witney will be filling the board seat recently left vacant by B.J. Cassin upon his retirement from the board on December 31, 2013.
Research and Markets: Smart Grid Round-Up, 2013 Research Report
Business Wire - Fri Feb 28, 2:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/tv32p7/smart_grid) has announced the addition of the "Smart Grid Round-Up, 2013" report to their offering.
Cerus to Present at the Cowen and Company 34th Annual Health Care Conference, on March 4, 2014
Business Wire - Thu Feb 27, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that William "Obi" Greenman, president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 34th Annual Health Care Conference at 11:20 AM ET on Tuesday, March 4, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 26, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cerus Shares Up -3.6% Since SmarTrend's Buy Recommendation (CERS)
Comtex SmarTrend(R) - Wed Feb 26, 9:23AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on February 11th, 2014 at $6.82. In approximately 2 weeks, Cerus has returned 3.58% as of today's recent price of $6.58.
Cerus Corporation Reports Fourth Quarter and Year-End 2013 Results
Business Wire - Tue Feb 25, 3:01PM CST
--2014 revenue guidance of $38-40 million; reflects potential negative impact to H1 sales from planned changes to distributor relationships.
Cerus to Release Fourth Quarter and Year End 2013 Results on February 25, 2014
Business Wire - Tue Feb 11, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2013 will be released on Tuesday, February 25, 2014, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the company's financial results and provide a general business overview and outlook.
Cerus (CERS) Soars: Stock Adds 6.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:39AM CST
Cerus Corporation was a big mover last session, as its shares rose nearly 7% on the day.
Can Cerus Corporation (CERS) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 7:31AM CST
Can Cerus Corporation (CERS) Continue to Rise?
2 Biotech Stocks Under $10 Triggering Breakouts
at The Street - Wed Jan 08, 6:00AM CST
Keep these under-$10 biotech stock on your radar.
Cerus Appoints North American Sales Team Leadership
Business Wire - Wed Dec 11, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today the appointments of Kenneth Trader as vice president, sales, North America, and Scott Buker as senior director, North American market development. Both will join the company in January 2014. Mr. Trader will be responsible for sales operations in North America, including planning for anticipated product launches as well as establishing and building the sales team responsible for product adoption. Mr. Buker will be responsible for key launch activities and for management of national accounts in North America.
Cerus Submits Final Module in the Premarket Approval (PMA) Application Process for INTERCEPT Plasma
Business Wire - Wed Dec 04, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today that it has submitted the fourth and final module for its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA), for review of the INTERCEPT Blood System for plasma.
Iceland National Blood Bank Signs INTERCEPT Platelet and Plasma Agreement with Cerus
Business Wire - Wed Nov 20, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that BloA deg bankinn, Iceland's national blood transfusion service at Landspitali University Hospital, has signed an agreement for the purchase of the INTERCEPT Blood System for platelets and plasma. BloA deg bankinn is the sole supplier of blood components in Iceland.
Cerus Announces Agreement with Health Canada for Regulatory Submission of the INTERCEPT Blood System for Platelets and Plasma
Business Wire - Wed Nov 06, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today that it has reached agreement with Health Canada regarding a regulatory submission for the INTERCEPT Blood System for platelets and plasma. Cerus plans to file with Health Canada for both products in the first half of 2014. Health Canada is the federal department in Canada that is responsible for review and authorization of drug, device and health products. Canada is supported by two blood services, Hema Quebec for the province of Quebec and Canadian Blood Services for the remainder of the country.
Financial Results Schedules, Approvals, Appointments, Product Launches, and Stock Movements - Analyst Notes on Allergan, Accuray, Cerus, Galena Biopharma, and ZELTIQ Aesthetic
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY), Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ: GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cerus Submits the Medical Device License Application to Health Canada for INTERCEPT Plasma
Business Wire - Mon Apr 07, 7:31AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that it has submitted its Medical Device license application to Health Canada for review of the INTERCEPT Blood system for plasma. This follows an agreement reached with Health Canada in November of last year to pursue regulatory submissions for both INTERCEPT platelets and plasma. Cerus plans to file its regulatory submission for platelets in the second quarter of 2014.
Shares of CERS Down 17.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 03, 11:19AM CDT
SmarTrend identified a Downtrend for Cerus (NASDAQ:CERS) on March 12th, 2014 at $6.04. In approximately 3 weeks, Cerus has returned 17.05% as of today's recent price of $5.01.
Cerus Down 16.6% Since SmarTrend Downtrend Call (CERS)
Comtex SmarTrend(R) - Thu Mar 27, 9:51AM CDT
SmarTrend identified a Downtrend for Cerus (NASDAQ:CERS) on March 12th, 2014 at $6.04. In approximately 2 weeks, Cerus has returned 16.56% as of today's recent price of $5.04.
Partnership to Initiate Development of Whole Blood Pathogen Inactivation for Sub-Saharan Africa
Business Wire - Wed Mar 26, 7:31AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that the Humanitarian Foundation Swiss Red Cross has granted funds to Swiss Tranfusion SRC (Blutspende SRK Schweiz) to adapt the INTERCEPT Blood System for red blood cells for pathogen inactivation and transfusion of whole blood, specifically for sub-Saharan African countries. The initial funding of 1.5 million Swiss Francs will support the feasibility phase of the project and completion of in vitro studies to support patient clinical trials.
Frank Witney Joins Cerus Board of Directors
Business Wire - Tue Mar 25, 7:31AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that Dr. Frank Witney, president and chief executive officer of Affymetrix, has joined its board of directors and the compensation committee. Dr. Witney joins the board with over 30 years of experience in the life science industry, specifically focused on corporate strategy and commercialization of products in the life science tools and diagnostics space. Dr. Witney will be filling the board seat recently left vacant by B.J. Cassin upon his retirement from the board on December 31, 2013.
Research and Markets: Smart Grid Round-Up, 2013 Research Report
Business Wire - Fri Feb 28, 2:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/tv32p7/smart_grid) has announced the addition of the "Smart Grid Round-Up, 2013" report to their offering.
Cerus to Present at the Cowen and Company 34th Annual Health Care Conference, on March 4, 2014
Business Wire - Thu Feb 27, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that William "Obi" Greenman, president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 34th Annual Health Care Conference at 11:20 AM ET on Tuesday, March 4, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 26, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cerus Shares Up -3.6% Since SmarTrend's Buy Recommendation (CERS)
Comtex SmarTrend(R) - Wed Feb 26, 9:23AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on February 11th, 2014 at $6.82. In approximately 2 weeks, Cerus has returned 3.58% as of today's recent price of $6.58.
Cerus Corporation Reports Fourth Quarter and Year-End 2013 Results
Business Wire - Tue Feb 25, 3:01PM CST
--2014 revenue guidance of $38-40 million; reflects potential negative impact to H1 sales from planned changes to distributor relationships.
Cerus to Release Fourth Quarter and Year End 2013 Results on February 25, 2014
Business Wire - Tue Feb 11, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2013 will be released on Tuesday, February 25, 2014, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the company's financial results and provide a general business overview and outlook.
Cerus (CERS) Soars: Stock Adds 6.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:39AM CST
Cerus Corporation was a big mover last session, as its shares rose nearly 7% on the day.
Can Cerus Corporation (CERS) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 7:31AM CST
Can Cerus Corporation (CERS) Continue to Rise?
2 Biotech Stocks Under $10 Triggering Breakouts
at The Street - Wed Jan 08, 6:00AM CST
Keep these under-$10 biotech stock on your radar.
Cerus Appoints North American Sales Team Leadership
Business Wire - Wed Dec 11, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today the appointments of Kenneth Trader as vice president, sales, North America, and Scott Buker as senior director, North American market development. Both will join the company in January 2014. Mr. Trader will be responsible for sales operations in North America, including planning for anticipated product launches as well as establishing and building the sales team responsible for product adoption. Mr. Buker will be responsible for key launch activities and for management of national accounts in North America.
Cerus Submits Final Module in the Premarket Approval (PMA) Application Process for INTERCEPT Plasma
Business Wire - Wed Dec 04, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today that it has submitted the fourth and final module for its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA), for review of the INTERCEPT Blood System for plasma.
Iceland National Blood Bank Signs INTERCEPT Platelet and Plasma Agreement with Cerus
Business Wire - Wed Nov 20, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that BloA deg bankinn, Iceland's national blood transfusion service at Landspitali University Hospital, has signed an agreement for the purchase of the INTERCEPT Blood System for platelets and plasma. BloA deg bankinn is the sole supplier of blood components in Iceland.
Cerus Announces Agreement with Health Canada for Regulatory Submission of the INTERCEPT Blood System for Platelets and Plasma
Business Wire - Wed Nov 06, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today that it has reached agreement with Health Canada regarding a regulatory submission for the INTERCEPT Blood System for platelets and plasma. Cerus plans to file with Health Canada for both products in the first half of 2014. Health Canada is the federal department in Canada that is responsible for review and authorization of drug, device and health products. Canada is supported by two blood services, Hema Quebec for the province of Quebec and Canadian Blood Services for the remainder of the country.
